CYMBATEX 30MG 30 CAP; duloxetine, antidepressants .
ACTIVE-INGREDIENT OF CYMBATEX 30MG 30 CAP
each delayed release capsule contains :active ingredients : duloxetine hydrochloride 33.65 mg . Equivalent to duloxetine 30 mg .
INDICATION OF CYMBATEX 30MG 30 CAP
treatment of major depressive disorder . Treatment of diabetic peripheral neuropathic pain . Treatment of generalised anxiety disorder . Cymbatex is indicated in adults .
DOSAGE OF CYMBATEX 30MG 30 CAP
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
major depressive disorder : the starting and recommended maintenace dose is 60 mg once daily with or without food . Dosages above 60 mg once daily , up to a maximum dose of 120 mg per day have been evaluated from a safety perspective in clinical trials . however , there is no clinical evidence suggesting that patients not respondding to the initial recommended dose may benefit from dose up-titrations . therapeutic response is usually seen after 2-4 weeks of treatment . after consolidation of the antidepressive response , it is recommended to continue treatment for several months , in order to avoid relapse . in patients responding to duloxetine , and with a history of repeated episodes of major depression , further long-term treatment at a dose of 60 to 120 mg /day could be considered . generalised anxiety disorder ; the recommended starting dose in patients with generalised anxiety disorder is 30 mg once daily with or without food . in patients with insufficient response ,
OVER-DOSAGE OF CYMBATEX 30MG 30 CAP
CONTRA-INDICATION OF CYMBATEX 30MG 30 CAP
hypersensitivity to the active substance or to any of the excipients concomitant use of duloxetine with non selective , irreversible monoamine oxidase inhibitors ( MAOIs ) is contraindicated . Liver disease resulting in hepatic impairment . Duloxetine should not be used in combination with fluvoxamine , ciprofloxacin , or enoxacin ( i.e. potent CYP1A2 inhibitors ) , since the combination results in elevated plasma concentrations of duloxetine . sever renal impairment ( creatinine clearance STORAGE OF CYMBATEX 30MG 30 CAP
store in a dry place , at a temperature not exceeding 30 C . KEEP OUT OF REACH OF CHILDREN
PACK OF CYMBATEX 30MG 30 CAP
carton box containing 1,2,3 (AL/AL) blisters each of 10 hard gelatin capsules with insert leaflet .
CYMBATEX 30MG 30 CAP MANUFACTURED BY